

Friday Satellite Symposia



HOW THE EXPERTS TREAT **ACUTE LYMPHOBLASTIC LEUKEMIA:** Case Discussions from Adolescent to Adult

IN-PERSON + LIVE STREAMING SATELLITE SYMPOSIUM

FRIDAY, DECEMBER 9, 2022

11:00 AM – 2:00 PM CST

PROGRAM CHAIR

Elias Jabbour, MD

For more information, visit us at...

gotoper.com



STAY CONNECTED! Follow us @GoToPER and share your thoughts by using #gotoPER.

Dear Colleague:

On behalf of Physicians' Education Resource®, LLC (PER®), we would like to welcome you and thank you for choosing to attend Medical Crossfire®: How the Experts Treat Acute Lymphoblastic Leukemia: Case Discussions From Adolescent to Adult.

The understanding of acute lymphoblastic leukemia (ALL) pathophysiology has expanded in recent years with the identification of new cytogenetic and molecular abnormalities and the development of novel targeted agents. Tyrosine kinase inhibitors, monoclonal antibodies, novel bispecific immune therapies, and chimeric antigen receptor (CAR) T cells have all been implemented to improve clinical outcomes. This satellite symposium presents an exciting opportunity to hear experts apply the latest practice-changing clinical trial data, evidence-based testing, and therapeutic strategies to individualize treatment planning for patients with ALL.

In working with PER®, we strive to make this activity, along with all PER® accredited continuing education (CE) activities, useful and impactful for health care professionals who are involved with the care of patients with ALL.

If there is anything that you need, if you experience an issue, or if you have an idea for a future activity that would help you in the care of your patients, please let us know.

We could not have our accredited CE activities without you, and we appreciate your commitment to learning about the latest advancements in the treatment of cancer. Let's work together to make this an educational experience that will make a positive difference for our patients!

We hope you enjoy your experience at this first-class PER® satellite symposium and that you can attend another PER® accredited CE activity soon.

Regards,

Elias Jabbour, MD

Professor of Medicine, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX

Jim Palatine, RPh, MBA

President
Physicians' Education Resource®, LLC
Cranbury, NJ
jpalatine@mjh Lifesciences.com

AGENDA

10:15 AM	Registration and Brunch	
11:00 AM	Welcome and Introductions	Elias Jabbour, MD
11:10 AM	Asparaginase and Beyond: New Drugs in Young Adult ALL	Rob Pieters, MD
11:40 AM	Incorporating Bispecific and Monoclonal Antibodies	Hagop M. Kantarjian, MD
12:10 PM	Assessing and Managing MRD in ALL	Sabina Chiaretti, MD, PhD
12:40 PM	Integrating TKI and Chemotherapy-Free Regimens in Management of ALL	Elias Jabbour, MD
1:10 PM	Integrating CAR T-cell Therapy and Bispecific Antibodies in ALL Management	Bijal Shah, MD, MS
1:40 PM	Question-and-Answer Session	All Faculty
1:50 PM	Program Summary	Elias Jabbour, MD
2:00 PM	Adjourn	

Upcoming PER® Conferences

2022

Inaugural International Congress Pediatric Oncology

December 16

2023

<i>The 1st Annual Hawaii Lung: A Multidisciplinary Case-Based Conference™</i>	Honolulu, HI	January 21
<i>20th Annual Winter Lung Conference®</i>	Hollywood, FL	February 3-5
<i>19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®</i>	Dallas, TX	February 4
<i>27th Annual International Congress on Hematologic Malignancies®</i>	Miami Beach, FL	February 23-26
<i>40th Annual Miami Breast Cancer Conference®</i>	Miami Beach, FL	March 2-5
<i>NYGU™ 16th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies</i>	New York, NY	March 10-11
<i>8th Annual School of Gastrointestinal Oncology®</i>	Orlando, FL	May 6
<i>7th Annual International Congress on Oncology & Pathology™: Towards Harmonization of Pathology and Oncology Standards</i>		May 6
<i>14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies</i>		May 13
<i>22nd Annual International Congress on the Future of Breast Cancer® East</i>	New York, NY	July 15-16
<i>24th Annual International Lung Cancer Congress®</i>	Huntington Beach, CA	July 27-29
<i>22nd Annual International Congress on the Future of Breast Cancer® West</i>	San Diego, CA	July 28-29
<i>20th Annual Meeting of the International Society of Gastrointestinal Oncology®</i>	Tempe, AZ	October 13-14
<i>21st Annual School of Breast Oncology®</i>	Atlanta, GA	November 2-4
<i>41st Annual CFS®: Innovative Cancer Therapy for Tomorrow®</i>	New York, NY	November 8-10
<i>18th Annual New York Lung Cancers Symposium®</i>	New York, NY	November 11



Virtual Conference



In-Person + Virtual Conference



In-Person Conference

Target Audience

The target audience for this activity is medical oncologists, hematologic oncologists, hematologists, hematopathologists, nurses, and other health care professionals involved in the treatment of ALL.

Learning Objectives

Upon completion of this activity, participants will be able to:

- Utilize cytogenetic and immunophenotype characteristics to create individualized treatment strategies for adults and pediatric patients with ALL
- Assess the current and emerging role of MRD assessment in determining prognosis and in planning treatment in of patients with ALL
- Evaluate the efficacy and safety of current and emerging therapies, including monoclonal antibodies and ADCs, as well as CAR T-cell therapies in the management of patients with ALL
- Place updated clinical trial data and evidence-based recommendations in the context of evolving management strategies utilizing antibody-based therapy in ALL management

Slides/e-Syllabus

Final slides will be uploaded to the e-syllabus on the PER® website by 12 PM EST on Monday, December 12, 2022. To access these materials, please visit <https://www.gotoper.com/ash22all-esyll>.

How to Request Credit

To complete the online evaluation and receive a certificate of credit or participation, please visit

<https://www.gotoper.com/ash22all-eval>.

The online evaluation and request for credit will be available immediately following the program and will remain available until Monday, January 23, 2023.


Accreditation/Designation of Credit

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this live activity for a maximum of 3.0 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Educational Grant Support

This activity is supported by educational grants from Amgen, Inc, Jazz Pharmaceuticals, Inc, Syndax Pharmaceuticals, Inc, and Takeda Pharmaceuticals U.S.A., Inc.



Thank you for attending **Medical Crossfire®: How the Experts Treat Acute Lymphoblastic Leukemia: Case Discussions From Adolescent to Adult!**

To register for upcoming accredited CE live activities
or to view our online accredited CE activities, please visit www.gotoper.com.

We appreciate your attendance and look forward to seeing you at future PER® accredited CE activities.

Faculty, Staff, and Planners' Disclosures

The following individuals have no relevant financial relationships with ineligible companies to disclose: the staff of Physicians' Education Resource®, LLC.

The following individuals have relevant financial relationships with ineligible companies to disclose*:

Faculty	Grant/Research Support	Consultant	Speakers' Bureau	Other
Sabina Chiaretti, MD, PhD				Advisory Board: AbbVie, Amgen, Inc, Gilead Sciences, Inc, Incyte
Elias Jabbour, MD	AbbVie, Adaptive Biotechnologies Corp, Amgen, Inc, Bristol Myers Squibb, Novartis Pharmaceuticals Corp, Pfizer Inc, Spectrum Pharmaceuticals Inc, Takeda Pharmaceutical Company Limited			
Hagop M. Kantarjian, MD	AbbVie, Agios Pharmaceuticals, Inc, Amgen, Inc, ARIAD Pharmaceuticals, Inc, Astex Pharmaceuticals, Inc, Bristol Myers Squibb, Cyclacel Pharmaceuticals, Inc, Daiichi Sankyo, Inc, Immunogen, Inc, Jazz Pharmaceuticals, Inc, Novartis Pharmaceuticals Corp, Pfizer Inc			Honoraria: AbbVie, Actinium Pharmaceuticals, Inc, Agios Pharmaceuticals, Inc, Amgen, Inc, Immunogen, Inc, Pfizer Inc, Takeda Pharmaceutical Company Limited
Rob Pieters, MD	Amgen, Inc, Celgene Corp, Pfizer Inc, Servier Pharmaceuticals LLC	Erytech Pharma Inc, Jazz Pharmaceuticals, Inc, Novartis Pharmaceuticals Corp, Servier Pharmaceuticals LLC	Amgen, Inc, Jazz Pharmaceuticals, Inc, Servier Pharmaceuticals LLC	
Bijal Shah, MD, MS	Jazz Pharmaceuticals, Inc, Kite/Gilead Sciences, Inc, Servier Pharmaceuticals LLC	Acrotech Biopharma Inc, Adaptive Biotechnologies Corporation, Amgen, Inc, AstraZeneca, Autolus Therapeutics plc, BeiGene, Bristol Myers Squibb/Celgene Corp, Kite/Gilead Sciences, Inc, Novartis Pharmaceuticals Corp, Precision BioSciences, Inc, Pfizer Inc, Pharmacyclics LLC		

**Information accurate at time of posting*

PER® has identified and mitigated all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This accredited CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing medical and/or nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to the diagnostic, treatment, and management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.

Physician Payments Sunshine Act

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.

Program Chair



Elias Jabbour, MD

Professor of Medicine, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX

Dr Elias Jabbour graduated from Saint Joseph's School of Medicine in 1998 and thereafter joined the Hôtel-Dieu de France University Medical Center as a resident. In 2001, he pursued a fellowship in Hematology-Oncology at Gustave Roussy. In 2003, he joined the University of Texas MD Anderson Cancer Center as a fellow in the Department of Hematology/Leukemia and Stem Cell Transplantation. In 2007, he joined the faculty in the Leukemia Department as an Assistant Professor.

Dr Jabbour is actively involved in research in both acute and chronic forms of leukemia. He was actively involved in clinical trials that led to the approval of several drugs in chronic myeloid leukemia (CML) and myelodysplastic syndromes. His research on resistance to imatinib and mutations of the protein kinase domain was presented at several international meetings and published in peer-reviewed journals. He is also developing tailored therapies for CML. He has authored or coauthored numerous publications and abstracts and serves as a reviewer for many scientific journals.

Faculty



Sabina Chiaretti, MD, PhD

Associate Professor
Department of Translational and Precision Medicine
Sapienza University
Rome, Italy

Sabina Chiaretti, MD, PhD, is an associate professor in the department of translational and precision medicine at Sapienza University in Rome, Italy. After obtaining a medical degree and residency in hematology in the pediatric and day units at Sapienza University, she earned a PhD at Sapienza University and at the Dana-Farber Cancer Institute in Boston, Massachusetts, focusing on genome-wide technologies for the in-depth analysis of lymphoid malignancies. Her main clinical focus is on the management of adult acute lymphoblastic leukemia, both in terms of translational research and development of clinical trials. She has served as the primary investigator/coordinator of most of the Italian clinical trials on acute lymphoblastic leukemia. She has authored or coauthored more than 130 peer-reviewed manuscripts and 4 book chapters.



Hagop M. Kantarjian, MD

Professor and Chair, Department of Leukemia
Samsung Distinguished Leukemia Chair in Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Hagop Kantarjian, MD, is a professor and chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas. He also is the Samsung Distinguished Leukemia Chair in Cancer Medicine and a nonresident fellow in health policy at Rice University's Baker Institute for Public Policy in Houston.

Dr Kantarjian's research focuses on translational-clinical developmental therapeutics in leukemia. In the past 3 decades, he has made several contributions that improved the prognosis and survival in patients

Faculty

with chronic myeloid leukemia (tyrosine kinase inhibitors, eg, imatinib, dasatinib, nilotinib, bosutinib, ponatinib, which improved the 10-year survival rate from 20% to 90%); in acute lymphocytic leukemia (HPER-CVAD regimen and its derivatives; antibodies including blinatumomab and inotuzumab); the discovery of decitabine for the treatment of myelodysplastic syndrome; and the discovery of clofarabine for the treatment of leukemias, among others. His research and collaborations were the basis for the FDA approvals of several leukemia drugs.



Rob Pieters, MD, PhD

Chief Medical Officer
Princess Máxima Center for Pediatric Oncology
Professor of Pediatric Oncology
University of Utrecht
Utrecht, Netherlands

Rob Pieters, MD, PhD, is chief medical officer at Princess Máxima Center for Pediatric Oncology and professor of pediatric oncology at the University of Utrecht, both in Utrecht, The Netherlands.

Dr Pieters earned his MSc in human movement science and his MD from the Free University of Amsterdam; in 1991, he obtained his PhD with a thesis on drug resistance in leukemia. After finishing his training in pediatrics in 1995, he received a clinical fellowship in pediatric oncology from the Dutch Cancer Society. He was head of pediatric oncology/hematology at the Erasmus MC Sophia Children's Hospital in Rotterdam and was a full professor in pediatric oncology at Erasmus University Rotterdam from 2000 through 2017; since 2017, he has been a full professor in pediatric oncology at the University of Utrecht. Dr Pieters is one of the founders of the Princess Máxima Center for Pediatric Oncology. This national center merged expertise from all former childhood cancer centers in The Netherlands, establishing it as the largest center in Europe for treatment and research of childhood cancer.



Bijal Shah, MD, MS

Associate Member, Department of Malignant Hematology
Moffitt Cancer Center
Tampa, FL


Bijal Shah, MD, MS, is an associate member in the Department of Malignant Hematology at H. Lee Moffitt Cancer Center and Research Institute. He serves as the clinical leader, with specific interests in mantle cell lymphoma and acute lymphocytic leukemia, and serves as the vice chair of medical oncology. Within this context, he strives to maximize the translational relationship between basic science and clinical care at Moffitt Cancer Center.

Did you miss one of our sessions?


Check out the On-Demand Video Updates
from the Annual Hematology Meeting

—Rapid Archive from→ **NEW ORLEANS**


Archive will be available 24 hours after the live program ends.



**Optimized use of MRD in
Hematologic Malignancies**




State-of-the-Art CMV Care




**Emerging Treatments for
Anemia in CKD**



**Holistic Approaches in
Sickle Cell Disease Treatment**




**Diagnosis and Treatment of
Hemolytic Anemias**




**Optimized Treatments for
ALL in Adolescents and Adults**




**Multidisciplinary Management
of BPDCN**




**Maximizing Clinical Practice
for Hodgkin Lymphoma**



**State-of-the-Art Care for
MF and PV**




**Exploring Gene Therapy in
Hemophilia B**



**Diagnosing Uncommon
Hematologic Disorders**



**Novel Therapies to Prevent
and Treat GvHD**



**Novel Treatments for Indolent
and Aggressive B-Cell Lymphomas**



**Treating Transfusion-Related
Iron Overload**



Scan the QR code below
or visit gotoper.com/ash22
to view the symposia archive.

 **PER**[®]
Physicians'
Education
Resource, LLC
gotoper.com